ArticleCJC open2026
Outcomes, Safety and Tolerability of Sacubitril-Valsartan over 3 years of Follow-up in Canadian Practice: Insights from the PARTHENON Registry.
Article in CJC open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Experience with sacubitril-valsartan in real-world patients with heart failure and reduced ejection fraction (HFrEF) is congruent with findings from clinical trials. Detailed assessment of safety and clinical outcomes in the Canadian context is less well explored. Methods: The PAtient RegisTry assessing effectiveness and safety of HEart failure treatment with LCZ696 acrOss CaNada (PARTHENON) was a prospective, observational, multicentre study. Patients with HFrEF who were prescribed sacubitril-valsartan were recruited from 32 sites across Canada and followed for at least 3 years. The primary outcome was the association between baseline natriuretic peptide levels and the combined endpoint of all-cause mortality or all-cause hospitalization. Secondary outcomes included incidence of hypotension, hyperkalemia, and renal impairment. Additionally, observed all-cause mortality was compared with risk-model predicted mortality. Results: A total of 996 patients were enrolled in the registry; 19.1% discontinued the study early, and 10.8% died. No statistically significant association occurred between baseline natriuretic peptide levels and all-cause mortality or all-cause hospitalization (adjusted hazard ratio 1.04; 95% confidence interval: 0.91-1.20). Clinically relevant hypotension, hyperkalemia, and an increased creatinine level were observed in 24%, 4%, and 24%, respectively. The mean absolute change in left ventricular ejection fraction over 18 months was +8.2% +/- 10.8%. The observed 3-year mortality rate was lower than the 3-year mortality rate predicted by the Meta-Analysis Global Group in Chronic (MAGGIC) risk score (10.8%, vs 29% +/- 13.7%); observed survival was higher than the Seattle Heart Failure Model predicted survival (89.2%, vs 53.4% +/- 26.4%). Conclusions: The PARTHENON registry confirms the safety and tolerability of sacubitril-valsartan in patients with HFrEF in a real-world setting. The registry also demonstrated improvement in left ventricular ejection fraction, and a lower mortality rate, compared to the predicted mortality rate in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.